EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

TIM ‐3 expression induces resistance to PD ‐1 inhibitor in G‐CSF ‐producing lung spindle cell carcinoma: A case report

Fumiko Hayashi, Kazumasa Akagi, Hirokazu Taniguchi iD, Toyoshi Matsutake, Hiromi Kawahara, Ichiro Sekine, Hiroshi Gyotoku, Shinnosuke Takemoto, Hiroshi Soda iD, Kazuto Ashizawa, Hiroshi Mukae

Thoracic Cancer · 2023

DOI: 10.1111/1759-7714.15149 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Thoracic Cancer, 2023. Verfasst von Fumiko Hayashi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung spindle cell carcinoma is an aggressive subtype of pleomorphic lung cancer resistant to cytotoxic chemotherapy. Programmed cell death‐1 (PD‐1) inhibitors have been reported to have clinical effects in patients with spindle cell carcinoma; however, the resistance mechanism to PD‐1 inhibitors is yet to be fully elucidated. Herein, we report the case of an 88‐year‐old man with G‐CSF‐producing spindle cell carcinoma who acquired resistance to PD‐1/PD‐ligand 1 (L1) inhibitor in an early setting after a remarkable response. A histopathological review of the resistant specimen revealed a low count of CD8 + T cells and a predominant presence of M2 and TIM‐3 + macrophages, indicating the presence of an immunosuppressive microenvironment. Our findings suggest a novel resistance mechanism to PD‐1/PD‐L1 inhibitors in G‐CSF‐producing spindle cell carcinoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsCarcinomaMaleHumansAged, 80 and overImmune Checkpoint InhibitorsGranulocyte Colony-Stimulating FactorHepatitis A Virus Cellular Receptor 2CD8-Positive T-LymphocytesProgrammed Cell Death 1 ReceptorLungB7-H1 AntigenTumor Microenvironment

Stichwörter der Autor:innen

M2 macrophageTIM-3acquired resistanceimmune checkpoint blockadespindle cell carcinoma

Substanzen

Immune Checkpoint InhibitorsGranulocyte Colony-Stimulating FactorHepatitis A Virus Cellular Receptor 2Programmed Cell Death 1 ReceptorB7-H1 Antigen

Autor:innen und Institutionen

  • Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
  • Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
  • Clinical Oncology Center, Nagasaki University Hospital, Nagasaki, Japan.
  • Department of Respiratory Medicine, Kouseikai Hospital, Nagasaki, Japan.
  • Department of Internal Medicine, Kouseikai Hospital, Nagasaki, Japan.
  • Department of Pathology, Kouseikai Hospital, Nagasaki, Japan.

ORCID-Profile: Hirokazu Taniguchi, Hiroshi Soda

Zitieren

APA

Hayashi, F., Akagi, K., Taniguchi, H., Matsutake, T., Kawahara, H., Sekine, I., Gyotoku, H., Takemoto, S., Soda, H., Ashizawa, K., & Mukae, H. (2023). TIM ‐3 expression induces resistance to PD ‐1 inhibitor in G‐CSF ‐producing lung spindle cell carcinoma: A case report. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15149

Vancouver

Hayashi F, Akagi K, Taniguchi H, Matsutake T, Kawahara H, Sekine I, et al. TIM ‐3 expression induces resistance to PD ‐1 inhibitor in G‐CSF ‐producing lung spindle cell carcinoma: A case report. Thoracic Cancer. 2023. doi:10.1111/1759-7714.15149

BibTeX
@article{Hayashi2023,
  author = {Hayashi, Fumiko and Akagi, Kazumasa and Taniguchi, Hirokazu and Matsutake, Toyoshi and Kawahara, Hiromi and Sekine, Ichiro and Gyotoku, Hiroshi and Takemoto, Shinnosuke and Soda, Hiroshi and Ashizawa, Kazuto and Mukae, Hiroshi},
  title = {TIM ‐3 expression induces resistance to PD ‐1 inhibitor in G‐CSF ‐producing lung spindle cell carcinoma: A case report},
  journal = {Thoracic Cancer},
  year = {2023},
  doi = {10.1111/1759-7714.15149}
}
Kostenlos starten →